In another study, EGFR-mutant NSCLC models did not respond to single-agent NVP-BEZ235, but when combined with a MEK inhibitor (AZD6244), tumor regression could be observed suggesting the key role of simultaneous PI3K and MEK inhibition in lung cancers with EGFR mutations [100]. The gene discussed is MAP2K7; the disease is lung cancer.